New antibody replacement therapy aims to shield vulnerable patients from serious infections
Disease control
Completed
This study tests a new intravenous immunoglobulin (IGIV) called PlasmaCap IG in adults and children aged 2 to 70 with primary immune deficiency diseases (PIDD). Participants receive regular infusions of the therapy for 12 months. The goal is to see if it prevents serious bacteria…
Phase: PHASE3 • Sponsor: Evolve Biologics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC